|
|
| U.S. Nuclear
Power Reactor Map
iOSAT™
received its approval from the US Food and Drug Administration in 1982,
and is the only full-strength tablet for radiation blocking which may
legally be sold in the US. Only iOSAT™ has passed all FDA tests for purity, quality, safety and efficacy.
Meets all FDA requirements
for potassium iodide as a radiation protective, and is labeled and packaged
in accordance with US government guidelines.
Has demonstrated all quality controls and passed all FDA requirements
for purity, quality, safety, efficacy.
Comes full strength (130
mg of potassium iodide per tablet) in accordance with FDA demands for complete
thyroid blocking.
|
|
|
|
|
www.fda.gov
|
"The
FDA recommends potassium iodide (KI) ... for thyroid blocking in
radiation emergencies. ... KI can be used to provide safe and effective
protection against thyroid cancer caused by irradiation ... The known
potential for potassium iodide to cause serious side effects in a small
sensitive population is not sufficient grounds from which to continue
to conclude, or even suggest, a significant and quantifiable proportion
of serious reactions."
[Federal Register, December 15, 1978; FDA: "Potassium Iodide as a
Thyroid Blocking Agent in Radiation Emergencies", December, 2000.]
|
www.ncrponline.org
|
"Radioiodines
are the primary internal radiation hazard during the first few weeks
after atomic bomb fallout ... [E]ffects from other radioactive
materials are considered relatively minor..."
[NCRP: Reports 42 and 55, New York Times, June 13, 2002.]
|
www.thyroid.org
|
"It
is essential that, one way or another, KI be available to protect the
public, especially children, in the event of a nuclear accident or act
of nuclear terrorism...[T]he United States, virtually alone among
developed nations, has failed to apply the principal lesson learned
from Chernobyl."
[ATA: Statement of November 7, 2001]
|
www.aap.org
|
"KI
can be 100% effective in preventing radiation-induced effects,
including thyroid cancer...[I]t should be kept in homes, schools, and
day care centers...[Those] at risk should receive KI before exposure,
if possible, or immediately afterward."
[American Academy of Pediatrics, News Release, May 19, 2003; Pediatrics, 2003]
|
www.nasonline.org
|
"Potassium
iodide pills should be available to everyone age 40 or younger...living
near a nuclear power plant...Federal agencies should keep a backup
supply and be prepared to distribute it to affected areas in the event
of a nuclear incident... The US government should... help states
implement plans for distributing potassium iodide."
[US National Academy of Sciences: Distribution of Potassium Iodide
in the event of a Nuclear Accident; National Research Council, 2004]
|
www.who.org
|
"Excess
thyroid cancer in children...from Chernobyl has been established... The
increase has been documented up to 500km from the accident site...the
Chernobyl accident has demonstrated that significant doses from
radioactive iodine can occur hundreds of kilometers beyond (ten-mile)
emergency planning zones... [Cancer risk] can be reduced or prevented
by implementation of iodine prophylaxis."
[WHO: Guidelines for Iodine Prophylaxis Following Nuclear Accidents; Update 1999. Geneva]
|
|
"It
is 14 years since the accident, and yet the most may still come... The
number of people with thyroid cancer began to increase about 5 years
after the accident. This number continues to rise... The number of
cases has exceeded expectations. Over 11,000 cases of thyroid cancer
have already been reported."
[United Nations Office for Humanitarian Affairs (OCHA): Chernobyl, A Continuing Catastrophe, 2000]
|
|
"FDA
recommends that KI be taken as soon as the radioactive cloud containing
iodine from the explosion [nuclear fission weapon] is close by. KI may
still have some protective even if taken 3 to 4 hours after exposure to
radioactive iodine...[one] dose should be taken every 24 hours."
|
|
"An
adequate supply of the radiation protective (thyroid blocking) agent,
potassium iodide for human use should be available regionally for
distribution to the general population and workers affected by a
radiological emergency."
[Report of the President's Commission on the Accident at Three Mile Island, John Kemeny, Chairman.
|
|
|
|
|
| U.S. Power Reactor
Radiation Zones
Contains no potassium iodate
or other adulterants. Contains only pure potassium iodide as the active
ingredient.
IOSAT [potassium iodide]
Is manufactured in the United States under strict FDA GMP guidelines,
and
holds an approved New Drug Application (NDA).
IOSAT [potassium iodide]
Was the first product of its kind (since 1982) and is the only product that
can be purchased by local, state and federal governments.
Is widely purchased by nuclear utilities.
IOSAT [potassium iodide]
offers unit dose packaging for maximum shelf-life and allows for individual
tablet distribution without fear of loss of packaging integrity.
|
|
|